Peptide Price Finder

Home · Clinical trials

Gonadorelin clinical trials

ClinicalTrials.gov lists 78 registered trials of Gonadorelin: 9 recruiting or about to, 5 running, 35 completed, 13 in phase 3, 11 with results posted. Recruiting sites are in China, Switzerland, Egypt, Germany, Netherlands, Spain. The largest is A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation (1,064 people).

78registered trials

9recruiting now

5running

35completed

13in phase 3

11with results posted

Recruiting: 9Running: 5Completed: 35Stopped or withdrawn: 6Status unknown: 2378trials
  • Recruiting 9
  • Running 5
  • Completed 35
  • Stopped or withdrawn 6
  • Status unknown 23

Where Gonadorelin is in testing

Registered trials by phase. Phase 3 trials are the large ones that decide approval.

1Early phase 1First doses in people
7Phase 1Safety and dosing
9Phase 2Does it work?
13Phase 3Large confirmatory trials
18Phase 4After approval
30Not phasedObservational and other

Timeline

Each bar runs from a trial's start to its planned end; faded bars have no end date. Click a bar to open the trial.

2016201820202022202420262028A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer · Recruiting · Phase 1 · 56 people · 2026-08-31 to 2027-04-30Effect of GnRH Agonist in FET · Recruiting · Phase 1, Phase 2 · 122 people · 2026-08-01 to 2027-08-01GnRH Agonist Pretreatment in Persistent Chronic Endometritis Undergoing FET · Recruiting · No phase · 150 people · 2026-06-01 to 2027-06-01Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis · Recruiting · Phase 4 · 120 people · 2025-08-01 to 2026-12-31A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study · Recruiting · Phase 1 · 106 people · 2024-11-11 to 2028-11-24NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. · Running · Phase 1 · 31 people · 2024-07-29 to 2026-09-11Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients · Recruiting · No phase · 222 people · 2024-02-19 to 2027-04-15The Effect of Dual Trigger (GnRH Agonist + hCG) for Final Maturation in Oocyte Donors With History of a Previous Cycle With Suboptimal Response to GnRH Agonist Only Trigger · Status unknown · No phase · 80 people · 2023-11-01 to 2025-04Contributions to Hypertension With Androgen Deprivation Therapy · Stopped or withdrawn · Phase 4 · 10 people · 2023-09-20 to 2025-07-16Adenomyosis and ART · Status unknown · Phase 4 · 500 people · 2023-03-27 to 2025-03Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy Rates · Status unknown · No phase · 144 people · 2022-10-01 to 2025-01-01GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients · Recruiting · Phase 2, Phase 3 · 80 people · 2022-07-13 to 2028-03-30RWE About QOL and Compliance of Patients With OFS in China · Completed · No phase · 562 people · 2022-03-01 to 2025-05-01Controlled Ovarian Stimulation Versus Modified Natural Cycles in Poor Responders · Status unknown · Phase 4 · 208 people · 2022-01-25 to 2024-09-30Efficacy of Prolonged GnRH Test in Male Adolescents With Postoperative HH · Status unknown · No phase · 20 people · 2022-01-01 to 2022-06-30Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study) · Running · Phase 4 · 55 people · 2021-11-22 to 2024-09-18GnRH Agonist Plus Hormone Replacement Therapy vs Hormone Replacement Therapy on IVF Outcomes · Completed · Phase 3 · 128 people · 2021-06-10 to 2022-01-03Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis · Recruiting · Phase 2, Phase 3 · 180 people · 2021-03-18 to 2026-06-18GnRH Therapy on Cognition in Down Syndrome · Recruiting · Phase 2, Phase 3 · 56 people · 2020-08-27 to 2028-12Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women · Running · Early phase 1 · 5 people · 2020-02-09 to 2022-07-24Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. · Completed · No phase · 44 people · 2019-09-25 to 2022-01-15Pulsatile Gonadotropin-releasing Hormone for Infertility in Non-obese Patients With Polycystic Ovary Syndrome · Status unknown · Phase 4 · 78 people · 2019-07-01 to 2020-12-30Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism · Completed · Phase 2 · 18 people · 2019-05-03 to 2025-08-31A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery · Running · Phase 2 · 188 people · 2019-04-15 to 2023-04-07Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia · Completed · No phase · 60 people · 2018-12-07 to 2023-09-01Accuracy of Ultrasound Markers Versus Biochemical Markers in Prediction of Ovarian Response in Obese Women Undergoing IVF/ICSI Treatment · Status unknown · No phase · 100 people · 2018-09 to 2019-09Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function · Completed · No phase · 19 people · 2018-02-07 to 2020-06-06The Influence of Gonadal Hormone Suppression on Adipocyte Lineage and the Microbiome · Stopped or withdrawn · No phase · 5 people · 2018-01-11 to 2019-12-18Administration of Kisspeptin in Patients With Hyperprolactinemia · Completed · Phase 2 · 36 people · 2017-11-17 to 2023-06-28Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol · Status unknown · Phase 4 · 120 people · 2017-08 to 2018-08The Relation of GnRH Treatment to QTc Interval in Transgender Females · Stopped or withdrawn · No phase · 3 people · 2017-05-01 to 2017-08-21Preventive Application of GnRH Antagonist on Early OHSS · Status unknown · Phase 4 · 175 people · 2017-01 to 2017-12Comparison of the Therapeutic Effects of VR and VR + GnRHa in the Treatment of Cesarean Scar Diverticula · Status unknown · No phase · 220 people · 2016-11 to 2018-01Combination of Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin Triggered by Normal Responder in GnRH-antagonist Cycles · Status unknown · Phase 3 · 1,000 people · 2016-09 to 2019-09Gonadotrophin Releasing Hormone Agonist Addition for Luteal Support in In-vitro Fertilization and Embryo Transfer Cycles · Status unknown · Phase 1 · 400 people · 2016-09 to 2017-09Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI · Completed · Phase 4 · 50 people · 2016-08-12 to 2017-08-24Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration · Status unknown · Phase 4 · 225 people · 2016-06-06 to 2024-12-31Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study) · Running · No phase · 300 people · 2016-05-22 to 2025-12-31Cryopreserved-thawed Embryo Transfer With or Without Gonadotropin Releasing Hormone Agonist · Completed · Phase 3 · 310 people · 2016-03 to 2018-05Endometrial Volume and Sub-endometrial Vascularity as Predictors of In-vitro Fertilization Success · Completed · No phase · 82 people · 2016-01-01 to 2017-12-03
RecruitingRunningCompletedStopped or withdrawnStatus unknownTodayNewest 40 of 78 trials

Where trials are recruiting

Countries with sites in trials that are recruiting now.

Recruiting now 9

A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer

Not yet recruitingPhase 156 peopleAstellas Pharma Global Development, Inc.2026-08-31 → 2027-04-30

Studying: Prostate Cancer · NCT07783282

About this trial

Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of testosterone in the body. One of the side effects of hormone therapy is hot flashes. There is an unmet medical need to treat hot flashes in men undergoing hormone therapy for prostate cancer. This study will help researchers understand if hormone therapy (enzalutamide, apalutamide or bicalutamide) affects the way fezolinetant is processed by the body in men with prostate cancer. The main aim of this study is checking levels of fezolinetant in the blood over tim…

Effect of GnRH Agonist in FET

Not yet recruitingPhase 1, Phase 2122 peopleRandomizedAssiut University2026-08-01 → 2027-08-01🇪🇬 Egypt

Studying: GnRH Agonist · NCT07653282

About this trial

To evaluate the impact of single dose GnRH agonist administration as luteal phase support on pregnancy outcomes in frozen ICSI cycle

GnRH Agonist Pretreatment in Persistent Chronic Endometritis Undergoing FET

Not yet recruiting150 peopleGuoxia Yang2026-06-01 → 2027-06-01

Studying: Chronic Endometritis · NCT07642700

About this trial

Women with PCE represent a treatment-resistant phenotype in whom the endometrial inflammatory and immune status remains abnormal despite antibiotic therapy. GnRH agonist pretreatment may be most beneficial in endometrial phenotypes marked by persistent or residual inflammatory impairment rather than in all frozen embryo transfer populations.We therefore conducted a single-center prospective cohort study to investigate whether GnRH-HRT, compared with non-GnRH-based preparations, improve clinical pregnancy and live birth in women with PCE undergoing FET,

Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis

RecruitingPhase 4120 peopleRandomizedLi-jun Ding2025-08-01 → 2026-12-31🇨🇳 China

Studying: Deep Infiltrating Endometriosis (DIE), Infertility · NCT07696351

About this trial

Deep infiltrating endometriosis is a severe form of endometriosis that may reduce fertility and negatively affect pregnancy outcomes after assisted reproductive treatment. Gonadotropin-releasing hormone agonist pretreatment may suppress endometriotic lesions, reduce inflammation, and improve endometrial receptivity, but its benefit before frozen-thawed embryo transfer remains uncertain. This randomized controlled study will evaluate whether ultra-long GnRH-a pretreatment before hormone replacement therapy improves clinical pregnancy outcomes in patients with deep infiltrating endometriosis un…

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

RecruitingPhase 1106 peopleNovartis Pharmaceuticals2024-11-11 → 2028-11-24🇩🇪🇳🇱🇪🇸🇨🇭 Germany, Netherlands, Spain, Switzerland +2 more

Studying: Metastatic Castration-Resistant Prostate Cancer · NCT06531499

About this trial

The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter identified as AAA617) in taxane-naïve adult participants with PSMA-positive mCRPC who progressed on a prior ARPI treatment with normal renal function or mild renal impairment (eGFR ≥ 60ml/min).

Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients

Recruiting222 peopleRandomizedMỹ Đức Hospital2024-02-19 → 2027-04-15🇻🇳 Vietnam

Studying: Adenomyosis, IVF, Frozen Embryo Transfer · NCT06239376

About this trial

This randomized clinical trial aims to assess the comparative effectiveness of two distinct endometrial preparation protocols for frozen embryo transfer (FET) among women with adenomyosis undergoing IVF/ICSI. Specifically, it seeks to address the following key questions: 1. Does the protocol involving the combination of GnRH agonist and letrozole for down regulation with exogenous steroids (GnRHa+AI - AC) result in a higher live birth rate compared to the use of exogenous steroids alone (AC) in women with adenomyosis undergoing frozen embryo transfer? 2. What are the common side effects of th…

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

RecruitingPhase 2, Phase 380 peopleRandomizedXiaojun Chen2022-07-13 → 2028-03-30🇨🇳 China

Studying: Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance · NCT05316935

About this trial

To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.

Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis

RecruitingPhase 2, Phase 3180 peopleRandomizedHopital Foch2021-03-18 → 2026-06-18🇫🇷 France

Studying: Endometriosis, Adenomyosis, Infertility, Female · NCT04356664

About this trial

Women suffering from endometriosis and/or adenomyosis may also suffer from infertility. GnRH agonist injection could improve implantation and therefore increase the pregnancy rate in these patients. This study was designed to evaluate effects of the additional of GnRH agonist (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen Embryon Transfer as compared to oestrogens and progestins only.

GnRH Therapy on Cognition in Down Syndrome

RecruitingPhase 2, Phase 356 peopleRandomizedNelly Pitteloud2020-08-27 → 2028-12🇨🇭 Switzerland

Studying: Down Syndrome, Cognitive Decline, Alzheimer Disease, Early Onset, Olfaction Disorders · NCT04390646

About this trial

Down syndrome (DS) is the most common chromosomal disorder; with the increasing life expectancy, about 80% of DS adults reach age 65 years old. Early Alzheimer's disease (AD) is the most common cause of death within this population. DS individuals already show AD neuropathology by the age of 30, while it becomes clinically recognized in their late forties. DS subjects also exhibit olfaction defects in adulthood. To date, there is no treatment available for the cognitive or olfactory defects in DS. The development of an effective treatment targeting cognitive dysfunction in DS adolescents/adul…

Active, not recruiting 5

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruitingPhase 131 peopleNovartis Pharmaceuticals2024-07-29 → 2026-09-11🇫🇷🇩🇪🇪🇸🇬🇧 France, Germany, Spain, United Kingdom +1 more

Studying: Metastatic Neuroendocrine Prostate Cancer · NCT06379217

About this trial

The purpose of this study is to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gastrin Releasing Peptide Receptor (GRPR) between the baseline and following targeted radioligand therapy (RLT). Study will use radioligand imaging (RLI) to determine predominantly expressed target on the surface of tumor cells. Based on predominant expression of target, corresponding RLT targeting PSMA, SSTR2, or GRPR RLT will be given for up to 6 cycles every 6 weeks as intravenous (i.v.) inje…

Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)

Active, not recruitingPhase 455 peopleUniversity of Colorado, Denver2021-11-22 → 2024-09-18🇺🇸 United States

Studying: Menopause, Estrogen Deficiency, Women, Aging · NCT05057546

About this trial

This study will evaluate changes in blood vessels around the heart (e.g., aorta and carotid arteries) and in the brain with the loss of female sex hormones (e.g., estrogen) during the menopause transition. The menopause transition is associated with declines in blood vessel function and increased risk for cardiovascular disease and Alzheimer's disease. Increasing evidence supports an early role for declines in blood vessel function and future development of Alzheimer's disease in aging men and women. This study will learn about the effects of changes in female sex hormones, such as estrogen, d…

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

Active, not recruitingEarly phase 15 peopleRandomizedLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center2020-02-09 → 2022-07-24🇺🇸 United States

Studying: Sleep Restriction · NCT04037605

About this trial

The purpose of this study is to 1) determine how hypothalamic-pituitary-adrenal axis (HPA axis) activation occurs with sleep restriction and 2) evaluate how hypothalamic-pituitary-gonadal axis (HPG axis) deactivation occurs with sleep restriction. The investigator will also examine the cognitive function associated with sleep restriction, including food intake and food cravings.

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruitingPhase 2188 peopleRandomizedRTOG Foundation, Inc.2019-04-15 → 2023-04-07🇨🇦🇺🇸 Canada, United StatesResults posted

Studying: Prostate Cancer · NCT03809000

About this trial

Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free survival when enhanced ADT is used compared to standard ADT.

Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)

Active, not recruiting300 peopleChinese University of Hong Kong2016-05-22 → 2025-12-31🇭🇰 Hong Kong

Studying: Prostate Cancer · NCT03703778

About this trial

The prostate gland is a clinically important male accessory sex gland and vital for its production of semen. Prostate cancer (PCa) is now ranked 3th in annual incidence of male cancer and ranked 5th for cancer-related death in men in Hong Kong which accounts for about 10.9 deaths per 100,000 persons. Its incidence is rising rapidly, almost tripled in the past 10 years. Despite the improvement in awareness of the disease and also increasing use of serum prostate specific antigen, many patients still presented at a late stage that beyond cure by local therapy. Together with those patients suffer…

Completed 35

To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)

CompletedPhase 3397 peopleRandomizedOrganon and Co2006-12-28 → 2007-07-07Results posted

Studying: Infertility · NCT00702845

About this trial

Clinical trial objectives are to investigate the efficacy and safety of a single injection of 100 μg Org 36286 in women weighing 60 kg or less to induce multifollicular development for controlled ovarian stimulation (COS), using daily recFSH as a reference.

Dysregulation of FSH in Obesity: Functional and Statistical Analysis

Completed99 peopleUniversity of Colorado, Denver2015-07 → 2021-06-30🇺🇸 United StatesResults posted

Studying: Obesity, Fertility · NCT02478775

About this trial

Excess maternal weight, especially obesity, influences almost every aspect of fertility, from conception to problems during pregnancy. The investigators will use novel statistical methods to clarify the hormonal changes behind reproductive health conditions. A better understanding of reproductive hormonal changes in obese women may offer a way to identify new treatments.

Females, Aging, Metabolism, and Exercise

Completed47 peopleRandomizedUniversity of Colorado, Denver2012-10 → 2017-10🇺🇸 United StatesResults posted

Studying: Obesity · NCT01712230

About this trial

This study is designed to determine whether a reduction in hormones (such as occurs during menopause) causes a decrease in calories burned during physical activity. This study will also determine whether a reduction in hormones decreases calories burned while sleeping, resting, and eating and whether an exercise intervention can prevent this.

Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women

Completed39 peopleUniversity of Colorado, Denver2014-07 → 2014-12🇺🇸 United StatesResults posted

Studying: Obesity, Fertility · NCT01894581

About this trial

The United States has the highest prevalence of obesity among all countries surveyed in 2012 by the Organization for Economic Cooperation and Development. Maternal obesity is linked with anovulation, menstrual cycle abnormalities, subfertility, fetal loss, obstetrical complications and congenital anomalies. Changes in reproductive hormones and diminished oocyte quality have also been demonstrated. A gap of knowledge exists as the mechanisms underlying these harmful effects are poorly understood and no specific treatments exist. This proposal will test the hypothesis that dietary omega-3 fatty…

Administration of Kisspeptin in Patients With Hyperprolactinemia

CompletedPhase 236 peopleMassachusetts General Hospital2017-11-17 → 2023-06-28🇺🇸 United StatesResults posted

Studying: Hyperprolactinemia, Hypogonadism · NCT02956447

About this trial

The goal of this study is to learn more about how kisspeptin, a naturally occurring hormone, affects women with high levels of prolactin (also called hyperprolactinemia). Subjects in one group will undergo blood sampling every 10 minutes over two 12-hour periods (one 12-hour period without any intervention and one 12-hour period with intravenous (IV) kisspeptin administration). Subjects in the second group will receive subcutaneous (SC) kisspeptin every 90 minutes for eight days.

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

CompletedPhase 218 peopleStephanie B. Seminara, MD2019-05-03 → 2025-08-31🇺🇸 United StatesResults posted

Studying: Hypogonadotropic Hypogonadism · NCT04648969

About this trial

The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.

A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation

Completed1,064 peopleMerck KGaA, Darmstadt, Germany2015-12-31 → 2017-03-16🇩🇪 Germany

Studying: Polycystic Ovary Syndrome · NCT02607293

About this trial

This is a Phase IV, prospective, observational, single arm, multicenter trial to identify the population at high risk of overstimulation associated with signs and symptoms of PCOS and examines the utility of 12.5 international units (IU) increment of Gonal-f® new pen for individualized controlled ovarian stimulation (iCOS).

Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation

CompletedPhase 4570 peopleRandomizedInstituto Valenciano de Infertilidad, IVI VALENCIA2007-01 → 2009-10🇪🇸 Spain

Studying: Infertility · NCT00633347

About this trial

Oocyte donation is a well established procedure in assisted reproduction treatments (ART). It is demonstrated that the use of hormonal substitution therapy, for the synchronization of the cycles between the recipients and the donors, provides good results, similar to the ones obtained with the natural cycle. In the patients - recipients with preserved ovarian function, the recipient's natural cycle is annulled, thus preventing the spontaneous Luteinizing Hormone surge. Simultaneously and while waiting for the suitable donor, her endometrium is prepared. When the donation occurs and fertilizati…

RWE About QOL and Compliance of Patients With OFS in China

Completed562 peopleFudan University2022-03-01 → 2025-05-01🇨🇳 China

Studying: Breast Cancer, Quality of Life, Hormone Receptor-positive Breast Cancer · NCT05122377

About this trial

The purpose of this study is to assess the patient's feedback from using GnRHa depot formulation in postoperative, premenopausal patients with hormone receptor-positive breast cancer.

Cryopreserved-thawed Embryo Transfer With or Without Gonadotropin Releasing Hormone Agonist

CompletedPhase 3310 peopleRandomizedCairo University2016-03 → 2018-05🇪🇬 Egypt

Studying: Infertility · NCT02736032

About this trial

Traditionally, the use of GnRH-a suppression was considered essential for adequate endometrial hormonal modulation in cryopreserved-thawed embryo transfer cycles. Several studies, however, have questioned its necessity for controlled endometrial preparation. Using a high dose of estradiol from day 1 of the cycle will suppress the gonadotroph, preventing folliculogenesis and excessive secretion of LH, allowing adequate endometrial preparation without GnRH-a.

Kisspeptin Administration in the Adult

CompletedPhase 1256 peopleMassachusetts General Hospital2009-06-23 → 2021-10-22🇺🇸 United States

Studying: Hypogonadotropic Hypogonadism, Kallmann Syndrome, GnRH Deficiency, PCOS · NCT00914823

About this trial

The goal of this study is to learn about the role of kisspeptin in the reproductive system. Kisspeptin is a naturally occurring hormone in humans that causes the release of other hormones, including gonadotropin-releasing hormone (GnRH) in the body.

Outcome of Two Protocols in Poor Responders in Assisted Reproductive Technology (ART) Cycle

CompletedPhase 3200 peopleRandomizedRoyan Institute2008-09 → 2010-01🇮🇷 Iran

Studying: Infertility · NCT01006954

About this trial

About 9 to 24 % of women undergoing in vitro fertilization (IVF) treatment respond poorly to the usual gonadotrophin stimulation protocol applied. Several induction ovulation treatments have been suggested for increasing pregnancy rate. In this study, the investigators will compare the outcome of Microflare protocol and Flare up regimen in poor responders.

Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist

CompletedPhase 4200 peopleRandomizedYazd Research & Clinical Center for Infertility2008-01 → 2008-12🇮🇷 Iran

Studying: Ovarian Stimulation · NCT00830492

About this trial

Objective: To compare the efficacy of using mild ovarian stimulation protocol and conventional stimulation protocol in IVF outcome. Design: Prospective randomized trial Setting: University IVF setting. Patient(s): The study compromised a total 200 subinfertile couple that women had regulary menstruation. Intervention(s): Patients were randomized to treatment clomiphene citrate, gonadotropin and GnRH antagonist (100 patients) or GnRH agonist and gonadotropin ( 100 patients). Main outcome measure: Clinical pregnancy rate. Key Words: clomiphene citrate, GnRH agonist, GnRH antagonist, in vitr…

GnRH Agonist Plus Hormone Replacement Therapy vs Hormone Replacement Therapy on IVF Outcomes

CompletedPhase 3128 peopleRandomizedTehran University of Medical Sciences2021-06-10 → 2022-01-03🇮🇷 Iran

Studying: Polycystic Ovary Syndrome, Infertility, Female · NCT05189873

About this trial

The study is conducted at Arash Women's Hospital on all women undergoing the frozen embryo transfer cycle. Patients who signed informed consent will be randomly divided into two groups. The first group will receive GnRH agonist plus hormone replacement therapy for endometrial preparation. Group 2 will receive hormone replacement therapy. The random allocation and final outcome of the study will be assessed by a person who is unaware of the study process. Also, the statistician will be unaware of the study process

Antagonist/Letrozole in Poor Responders

CompletedPhase 1, Phase 2120 peopleRandomizedYazd Research & Clinical Center for Infertility2008-06 → 2009-02🇮🇷 Iran

Studying: Ovarian Stimulation · NCT00823004

About this trial

Failure to respond to controlled ovarian hyperstimulation (COH) is still a major concern in assisted reproduction and there is no consensus on the ovarian stimulation choice regime for poor responders. Aim: To evaluate and compare the efficacy of a microdose GnRH agonist flare (MF) and a GnRH antagonist/letrozole (A/L) protocols in poor responders undergoing in vitro fertilization (IVF). Methods: One hundred eighty poor responder patients will be randomized to an ovarian stimulation protocol with either a MF or a letrozole and high dose FSH/hMG and flexible GnRH antagonist protocol.

IVF Treatment in Women With Immature Oocytes in Previous Cycle

Completed100 peopleRandomizedSheba Medical Center2015-02-01 → 2020-06-01🇮🇱 Israel

Studying: Infertility · NCT02368964

About this trial

In standard IVF stimulation cycle,human chorionic gonadotropin (hCG) is usually used at the end of controlled ovarian hyperstimulation (COH) as a surrogate to only the luteinizing hormone (LH) surge. Yet, the last dose of follicle stimulating hormone (FSH) is usually given between 12-24 hours before the hCG triggering dose.One protocol used at the investigators unit, after a cycle with low proportion of mature oocytes per number oocytes retrieved, is triggering with high dose hCG (500 mcg)-38 hours prior to oocyte aspiration. Lately, new researches showed that dual triggering of final oocyte …

Administration of GnRH Antagonist to Oocyte Donation Recipients

Completed100 peopleCentro Ginecologia y Obstetricia.2004-01 → 2007-12🇪🇸 Spain

Studying: Pregnancy, Embryo Implantation · NCT00635258

About this trial

This prospective and randomized study was performed to evaluate whether the replacement of GnRH agonist by a GnRH antagonist in oocyte donation recipients during endometrial preparation has any impact on pregnancy and implantation rates.

Effect of Ultrasound Guided Embryo Transfer on Pregnancy Rates

Completed90 peopleRandomizedAin Shams Maternity Hospital2009-09 → 2011-08🇪🇬 Egypt

Studying: Infertility · NCT01810601

About this trial

To assess the effect of transabdominal ultrasound guided embryo transfer on the pregnancy rates versus clinical touch technique

Endometrial Volume and Sub-endometrial Vascularity as Predictors of In-vitro Fertilization Success

Completed82 peopleCairo University2016-01-01 → 2017-12-03

Studying: Reproductive Techniques, Assisted · NCT02381821

About this trial

100 patients aged 21-40 years old, diagnosed as primary or secondary infertility These patients are then assigned to receive ICSI treatment (ovulation induction, . They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation. Intervention(s) All patients will undergo 3D ultrasound to measure the thickness of the junctional zone at day 21 of the cycle.

Endometriosis Trial: Study of NBI-56418 in Endometriosis

CompletedPhase 276 peopleRandomizedAbbott2005-04 → 2006-06🇺🇸 United States

Studying: Endometriosis · NCT00109512

About this trial

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with subjects randomized to one of three treatment groups, placebo, 75 mg and 150 mg in a 1:1:1 ratio. Study drug was administered once daily for 12 weeks. After the last dose at the end of Week 12, follow-up continued every 4 weeks for 12 weeks.

Neuropeptides in Human Reproduction

CompletedPhase 161 peopleMassachusetts General Hospital2014-04-30 → 2016-05-31🇺🇸 United States

Studying: Hypogonadotropic Hypogonadism · NCT01952782

About this trial

The investigators are seeking healthy volunteers and volunteers with reproductive disorders for the study of the role of dynorphin in the reproductive system. Dynorphin is a naturally occurring opioid hormone that is blocked by naloxone. We hypothesize that naloxone, by blocking dynorphin, will stimulate production of gonadotropin-releasing hormone (GnRH) and kisspeptin, two other naturally occurring reproductive hormones.

Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia

Completed60 peopleSeattle Institute for Biomedical and Clinical Research2018-12-07 → 2023-09-01🇺🇸 United States

Studying: Metastatic Prostate Cancer, Androgen Deprivation Therapy · NCT03867357

About this trial

Prostate cancer (PCa) is the most common cancer among men and is even more common in the military and veteran population. For patients with advanced prostate cancer, the most common treatment includes lowering the levels of the hormone testosterone as much as possible. This is called "androgen deprivation therapy" or "ADT". Unfortunately, ADT also causes patients to be fatigued, weak and to loose muscle. This is often referred to as "sarcopenia" and it leads to falls, poor quality of life and higher risk of death. Currently, there is no treatment for sarcopenia because the investigators do not…

Neoadjuvant Endocrine Therapy in Breast Cancer

CompletedPhase 246 peopleGuangdong Provincial People's Hospital2012-09 → 2017-07🇨🇳 China

Studying: Highly Endocrine Responsive Operable Breast Cancer · NCT03397537

About this trial

The study aimed to compare the duration to complete or partial response (CR/PR) and the overall response rates (ORR) after six months of neoadjuvant endocrine therapy between pre-menopausal group and post-menopausal group with highly endocrine responsive operable mammary carcinoma.

Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.

Completed44 peopleFundacion Dexeus2019-09-25 → 2022-01-15🇪🇸 Spain

Studying: Infertility, IVF, Preimplantation Diagnosis · NCT04108039

About this trial

To examine whether the number of euploid embryos following ovarian stimulation with micronized progesterone is equivalent as compared with the number of embryos after ovarian stimulation with the use of a GnRH antagonist in patients undergoing ovarian stimulation for IVF or intracytoplasmatic sperm injection (ICSI).

Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

CompletedPhase 1, Phase 243 peopleUniversity of Southern California2010-11-02 → 2017-02-02🇺🇸 United States

Studying: Prostate Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer · NCT01240629

About this trial

This is a research study for advanced prostate cancer. An experimental drug called AN-152 (also known as AEZS-108) will be used. The purpose of this study is to test the safety, tolerability and benefits of an experimental drug called AN-152. The participants tumor will be tested for expression of this receptor (using an old biopsy). If the participants cancer does not have this receptor, participants will not be eligible to participant in this study. AN-152 (AEZS-108) is administered intravenously (IV) over 2 hours and will be given at the specified dose every 3 weeks. Premedication with de…

Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males

Completed30 peopleLund University2015-03 → 2015-06

Studying: Hypogonadism, Male · NCT03541395

About this trial

The study is designed to identify and validate new protein biomarkers in blood related to testosterone activity. Thirty healthy young males underwent pharmaceutical castration to lower testosterone levels. After three weeks the subjects received an intramuscular injection of testosterone undecanoate. Blood samples from just before pharmaceutical castration, three weeks after castration, and one week after injection of testosterone undecanoate were collected representing normal testosterone levels, low testosterone levels, and testosterone at eugonadal levels.

Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function

Completed19 peopleRandomizedUniversity of Colorado, Denver2018-02-07 → 2020-06-06🇺🇸 United States

Studying: Cognitive Impairment, Estrogen Deficiency, Menopause, Endothelial Dysfunction · NCT03112226

About this trial

Complaints about memory and thinking are common in women as they go through menopause. The female hormone estrogen is important for both the health of both the brain and the blood vessels. In Alzheimer's disease there is damage to the blood vessels in the brain. This study will look at how the loss of the female hormone estrogen affects brain function and the health of blood vessels.

Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation

Completed15 peopleFundacion Dexeus2012-07 → 2013-12🇪🇸 Spain

Studying: INFERTILITY, Fertility Preservation, Ovulation Induction, Vitrification · NCT01645241

About this trial

The purpose of this study is to evaluate the clinical pregnancy rate per embryo transfer in oocytes recipients obtained after ovarian stimulation during the luteal phase of oocytes donors . This study will be performed in egg recipients and donors but this type of treatment is meant to be implemented in fertility preservation patients

Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Premature Puberty

Completed13 peopleRandomizedRegion Örebro County2015-05 → 2017-12🇸🇪 Sweden

Studying: Puberty, Precocious · NCT02431416

About this trial

The purposes of the study is to investigate whether circulating levels of ghrelin decreases after an iv injection of GnRH in girls with suspected central premature puberty and to investigate the effects of different post sampling handling on the preservation of acylated ghrelin.

Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism

Completed12 peopleRandomizedUniversity of Aarhus2007-09 → 2009-09🇩🇰 Denmark

Studying: Hypogonadism · NCT00613288

About this trial

Testosterone(T) has known effects on many organ systems, although many of its metabolic actions are unrevealed. T is an anabolic hormone stimulating protein synthesis but this effect has barely been investigated in controlled studies. It also has lipolytic actions influencing body composition, but little is known of its regional impact on fat tissue. T affects insulin sensitivity. There is an increased incidence of hypogonadism in type 2 diabetes, and among patients with hypogonadism there is an increased incidence of type 2 diabetes. The actions of testosterone on glucose metabolism are unkno…

Psychostimulant Abuse - Novel Treatment Approaches - 1

CompletedPhase 1National Institute on Drug Abuse (NIDA)2001-12🇺🇸 United States

Studying: Cocaine-Related Disorders · NCT00000325

About this trial

To determine if acute assessments of profasi and factrel affect plasma cocaine levels and cocaine-induced behavioral changes in men.

Short-Term Androgen Priming Before COS Using Aromatase Inhibitor and hCG During Early-Follicular-Phase GnRH Antagonist Administration - a Randomized Controlled Trial

CompletedPhase 4RandomizedCopenhagen University Hospital, Rigshospitalet🇩🇰 Denmark

Studying: Infertility · NCT00286364

About this trial

We want to investigate if early follicular phase downregulation and androgen priming, by use of GnRH antagonist, aromatase inhibitor and hCG before COH in a short protocol, shows signs of improvement compared to standard short antagonist protocol

Stopped early or withdrawn 6

Contributions to Hypertension With Androgen Deprivation Therapy

TerminatedPhase 410 peopleRandomizedUniversity of Colorado, Denver2023-09-20 → 2025-07-16🇺🇸 United StatesResults posted

Studying: Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction · NCT05700903

About this trial

This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a significant role in control of blood pressure. The results fro…

The Influence of Gonadal Hormone Suppression on Adipocyte Lineage and the Microbiome

Terminated5 peopleUniversity of Colorado, Denver2018-01-11 → 2019-12-18🇺🇸 United States

Studying: Adipose Tissue, Microbiome, Menopause · NCT03396978

About this trial

This research study plans to learn more about the role of female sex hormones on adipose tissue (or fat) and the gut microbiome (or the organisms that are in your digestive tract). The rationale for this study is that the rate at which women gain fat (especially in the stomach region) increases after menopause. It is thought to be due to the loss of estrogen because post-menopausal women who take estrogen gain less weight than those who do not take estrogen. Gut bacteria process estrogen and help determine the types of estrogen that circulate in the body. These bacteria can be changed with lif…

The Relation of GnRH Treatment to QTc Interval in Transgender Females

Terminated3 peopleUniversity of California, San Francisco2017-05-01 → 2017-08-21🇺🇸 United States

Studying: Gender Dysphoria · NCT03078829

About this trial

Background: The QT interval of the electrocardiogram (ECG), corrected for heart rate (QTc), is a measure of the duration of ventricular repolarization and is a widely used marker of ventricular arrhythmia risk. Testosterone has a shortening effect on QTc length, and the QTc interval in males is shorter than in females after the onset of puberty. Transgender female adolescents are treated with GnRH agonists or spironolactone that suppress endogenous testosterone secretion and might increase the QT interval sufficiently to increase the risk for malignant ventricular arrhythmias. There are no cur…

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

TerminatedPhase 47 peopleRandomizedUConn Health2012-04 → 2014-12🇺🇸 United StatesResults posted

Studying: Endometrial Receptivity, Ovarian Hyperstimulation Syndrome · NCT01606709

About this trial

The purpose of this study is to compare gene expression profiles in endometrial biopsies during the window of implantation after triggers of oocyte maturation using GnRH agonist or hCG and compared with their natural cycles in order to identify genes that may be dysregulated in GnRH agonist-triggered cycles. The investigators also intend to evaluate patients feeling of well being and physical quality of life after GnRH agonist trigger compared with hCG trigger.

Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy

WithdrawnPhase 4RandomizedEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2007-07-18 → 2010-07-22🇺🇸 United States

Studying: Ovarian Function, Preservation of Ovarian Function · NCT00507780

About this trial

This study will examine whether the drug cetrorelex acetate (Cetrotide\[Registed Trademark\]) can protect ovarian function in women undergoing chemotherapy. Some cancer treatments are known to cause a change in women's periods or to cause menstruation to stop completely, so that they cannot become pregnant. Cetrorelex acetate has been used for many years to lower hormone levels and stop periods in patients undergoing in vitro fertilization treatments. This study will see if making the ovaries inactive may protect them from being affected by certain cancer drugs, and thus preserve fertility. W…

Status unknown 23

The Effect of Dual Trigger (GnRH Agonist + hCG) for Final Maturation in Oocyte Donors With History of a Previous Cycle With Suboptimal Response to GnRH Agonist Only Trigger

Unknown status80 peopleRandomizedEmbryolab Fertility Clinic2023-11-01 → 2025-04🇬🇷 Greece

Studying: Ovarian Stimulation, Human Chorionic Gonadotropin, Oocyte Donors · NCT06142708

About this trial

The goal of this clinical trial is to compare GnRH-agonist trigger with dual GnRH-agonist and HCG trigger in oocyte donors. The main questions it aims to answer are: * Maturation rate (Metaphase II/ Total number of COCs collected) * Fertilization rate * Embryo quality day 3 * Fragmentation rate embryo day 3 * Blastulation rate (Day5/6/7) * Quality of blastocyst (Gardner criteria) Participants will undergo controlled ovarian stimulation with a GnRH antagonist protocol Researchers will compare the effects of final maturation with GnRH-agonist trigger to a dual trigger (hCG and GnRH-a)

Adenomyosis and ART

Unknown statusPhase 4500 peopleRandomizedAzienda Ospedaliero-Universitaria di Modena2023-03-27 → 2025-03🇮🇹 Italy

Studying: Adenomyosis · NCT05937490

About this trial

The goal of this clinical trial is to: * Prospectively investigate the association of Adenomyosis with fertility outcomes in relation to COH protocols for ART (long or ultra- long protocol) with a preventive high-dose anti-inflammatory progestin such as DNG and to assess their association with pregnancy and neonatal outcomes (preterm delivery,pre-eclampsia,Caesarean section,fetal malpresentation,small for gestational age,low birth weight and postpartum hemorrhage). * Understand how the endometrial interface by studying the response of progesterone and DNG stimulated decidualization markers, c…

Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy Rates

Unknown status144 peopleRandomizedShaare Zedek Medical Center2022-10-01 → 2025-01-01🇮🇱 Israel

Studying: Luteal Phase Support · NCT05838105

About this trial

The aim of the study is to compare the pregnancy rate between women treated with Gonadotropin Releasing Hormone (GnRH) agonist together with Human Chorionic Gonadotropin (HCG) and standard luteal support with progesterone following transfer of frozen embryos in in-vitro-fertilization (IVF) natural cycles.

Controlled Ovarian Stimulation Versus Modified Natural Cycles in Poor Responders

Unknown statusPhase 4208 peopleRandomizedUniversity Hospital, Ghent2022-01-25 → 2024-09-30🇧🇪 Belgium

Studying: Ovarian Reserve, Poor Responders, IVF · NCT04487925

About this trial

This is a prospective, randomized, single center, phase 4 controlled trial. The study will compare the efficacy of two different strategies for the management of predicted poor response patients under stimulation for IVF/ICSI: up to three MNC cycles (group 1) versus a single GnRH antagonist CFA (group 2).

Efficacy of Prolonged GnRH Test in Male Adolescents With Postoperative HH

Unknown status20 peopleHuashan Hospital2022-01-01 → 2022-06-30🇨🇳 China

Studying: Hypogonadotropic Hypogonadism · NCT05184374

About this trial

The Hypogonadotropic Hypogonadism(HH) could be caused by sellar lesions, sellar surgery or sellar radiotherapy. The incidence of HH after sellar surgery was higher in men than in women, and the therapy of HH was insufficient. Gonadotropin-releasing hormone(GnRH) stimulation test is used to evaluate the function of pituitary-gonadal axis. GnRH can be used to diagnose and treat fertility disorders and other endocrine disorders caused by HH. After a single injection of GnRH, the patients with poor response of luteinizing hormone and follicle stimulating hormone need to take extended provocation t…

Pulsatile Gonadotropin-releasing Hormone for Infertility in Non-obese Patients With Polycystic Ovary Syndrome

Unknown statusPhase 478 peopleRandomizedRenJi Hospital2019-07-01 → 2020-12-30🇨🇳 China

Studying: Polycystic Ovary Syndrome, Infertility, Ovulation Disorder · NCT03989024

About this trial

Polycystic ovary syndrome (PCOS) patients are often accompanied by infertility. Non-obese PCOS infertility is more difficult to treat than obese PCOS. The study included non-obese PCOS patients who had not recovered from regular menstruation after six months of metformin treatment. Half of the patients were treated with clomiphene for ovulation induction and half with GnRH pulse therapy.

Accuracy of Ultrasound Markers Versus Biochemical Markers in Prediction of Ovarian Response in Obese Women Undergoing IVF/ICSI Treatment

Unknown status100 peopleCairo University2018-09 → 2019-09🇪🇬 Egypt

Studying: Invitro Fertilization · NCT03684824

About this trial

After detailed history and examination, long luteal protocol will be used for controlled ovarian hyperstimulation, so the patient will start treatment in day 21 of previous cycle, then in the early follicular phase of next cycle day 2-3 will have transvaginal sonography for assessment of total ovarian volume and number of antral follicles measuring (2-10mm) in diameter. On the same day a venous sample will be obtained for the measurement of AMH, basal FSH and E2 levels

Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol

Unknown statusPhase 4120 peopleRandomizedCairo University2017-08 → 2018-08🇪🇬 Egypt

Studying: Invitro Fertilization · NCT03263299

About this trial

Ovarian stimulation will be done using the Microdose flare-up regimen. The patient will receive diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation will be initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day. Follicular monitoring began from the ninth day of the cycle by serial vaginal ultrasonography and measurement of serum E2 levels. IM injections of 10000 IU HCG (Choriomon; IBSA, Germany) will be injected when at least 2 follicles 18 mm were observed on ultrasonography. O…

Preventive Application of GnRH Antagonist on Early OHSS

Unknown statusPhase 4175 peopleRandomizedFirst Affiliated Hospital, Sun Yat-Sen University2017-01 → 2017-12🇨🇳 China

Studying: Ovarian Hyperstimulation Syndrome, GnRH Antagonist, Aspirin, Vascular Endothelial Growth Factor · NCT03188471

About this trial

Ovarian hyperstimulation syndrome is an iatrogenic complication of controlled ovarian stimulation. Ovarian hyperstimulation syndrome prevention is a multistage process and more important than treatment.Preventive administration of GnRH antagonist for high risk OHSS patients from the day of oocyte retrieval is not investigated. Besides, the relevant mechanism is not clear yet. Here we designed a prospective randomized study to investigate whether GnRH anatagonist treatment after oocyte retrieval is more effective in preventing early ovarian hyperstimulation syndrome development than traditional…

Comparison of the Therapeutic Effects of VR and VR + GnRHa in the Treatment of Cesarean Scar Diverticula

Unknown status220 peopleRandomizedXipeng Wang2016-11 → 2018-01🇨🇳 China

Studying: Cesarean Scar Diverticula · NCT02932761

About this trial

Cesarean scar diverticula (CSD) is a novel recognized cause of postmenstrual abnormal uterine bleeding in women. No clinical guidelines have been issued for the management of CSD. The investigators have previously demonstrated that vaginal repair of CSD was an relative effective treatment of CSD. However, only 28.2% of the CSD patients normalized to less than 7 days of menstruation, whereas 51.2% of women had 7 to 10 days of menstruation at 6 months post vaginal repair. Postoperative menstruation may contribute to surgical site infections, which may subsequently affect the healing of uterine s…

Combination of Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin Triggered by Normal Responder in GnRH-antagonist Cycles

Unknown statusPhase 31,000 peopleRandomizedTel-Aviv Sourasky Medical Center2016-09 → 2019-09

Studying: In-vitro Fertilization · NCT02862782

About this trial

Background The trigger for the final maturation of the ovum by providing integration of Human Chorionic Gonadotropin (hCG) and Gonadotropin - releasing hormone (GnRH) agonist was first introduced long ago, but clinically not accepted until the advent of GnRH antagonist protocol in IVF treatment. In a recently published work which compared two types of ovulation induction (standard dose of hcg and in combination of GnRH agonist) in women with normal ovarian response, there was a statistically significant increase in the rates of implantation, clinical pregnancies and live births rates by prov…

Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration

Unknown statusPhase 4225 peopleRandomizedMansoura University2016-06-06 → 2024-12-31🇪🇬 Egypt

Studying: Infertility · NCT02330770

About this trial

Comparing the reproductive outcomes of intracytoplasmic sperm injection (ICSI) cycles in women at risk of ovarian hyperstimulation syndrome (OHSS) subjected to gonadotropin releasing hormone (GnRH) antagonist protocol followed by trigger with concomitant GnRH agonist (GnRHa) and low-dose human chorionic gonadotropin (HCG) administration (dual trigger), GnRHa trigger with single luteal low-dose HCG or GnRHa trigger with multiple luteal low-doses HCG

Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis

Unknown status50 peopleRandomizedThe First Affiliated Hospital of Zhengzhou University2016-01 → 2017-01🇨🇳 China

Studying: Clinical Pregnancy Rate · NCT03006406

About this trial

Gonadotropin-releasing hormone analogue (GnRH-a) is a synthetic decapeptide compound which can down-regulate pituitary function causing a temporary low estrogen state. Since endometriosis is an estrogen-dependent disease, the use of long-acting GnRH-a can control the growth of endometriosis by inhibiting ovary function.Some scholars have found that, for adenomyosis patients who received a super long protocol (pretreatment of long-acting GnRH-a for 1-2 months) in IVF treatment, the pregnancy outcome is comparable to that of the controls with normal uterus. Thus, the aim of this study is to comp…

Efficacy and Safety of Medication Used to Stimulate Ovulation

Unknown statusPhase 4666 peopleRandomizedCreate Fertility Center2015-10 → 2020-09🇨🇦 Canada

Studying: IVF Cycle, Ovarian Stimulation, Egg Retrieval, Pregnancy · NCT02715336

About this trial

Individuals undergoing In Vitro Fertilization must undergo controlled ovarian hyperstimulation (COH) to produce enough quality eggs for fertility treatment. Ovarian follicular responsiveness to COH with gonadotropins is extremely variable between patients and even from cycle to cycle for the same patient. Achieving an ideal follicular response is critical to the success of assisted reproduction treatment (ART). Patients have been classified as 'poor', 'normal' or 'high' responders, which dictate the amount of gonadotropins that they receive. It is still important to develop treatments with hig…

LH Response to GnRH Test in Prepubescent Girls Under 6 Years

Unknown status60 peopleUniversity of Aarhus2013-09 → 2014-09🇩🇰 Denmark

Studying: Precocious Puberty · NCT01944488

About this trial

The project aims to establish the normal LH and FSH response to a standardized GnRH dose in healthy girls below 6 years of age, and compares the normal GnRH response to the GnRH response in girls with early puberty development. The novel data may help to determine whether the girl is in early puberty or not. Healthy girls under 6 years of age attending routine examinations including an i.v. line for other causes are included in this study. Our examinations also include bone age determination, Tanner stage determination, and anthropometric measures (height and weight). 10 healthy girls in eac…

Evaluation of Granulosa Cells Function After IVF Protocols

Unknown status28 peopleRandomizedHospital de Clinicas de Porto Alegre2013-09 → 2014-10🇧🇷 Brazil

Studying: Infertility, In Vitro Fertilization Protocols · NCT01946022

About this trial

This study is intended to evaluate ovarian cells after being submitted do different in vitro fertilization protocols. The investigators will analyze hormones secretion and intracellular mechanisms of these cells comparing the GnRH agonist protocol and the GnRH antagonist protocol.

Frozen Embryo Transfer in Natural and Hormonal Replacement Cycles

Unknown statusPhase 3460 peopleRandomizedRoyan Institute2012-09 → 2015-10🇮🇷 Iran

Studying: Infertility · NCT02251925

About this trial

This study is a prospective randomized controlled trial to compare the pregnancy outcomes of frozen embryo transfer in natural and hormonal replacement cycles. The study population consisted of all infertile women with regular menstrual cycles who will undergo IVF/ICSI and frozen embryo transfer in Reproductive Biomedicine Research Center, Royan institute, Tehran Iran.

The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol

Unknown statusPhase 3200 peopleRandomizedEuropean Hospital2012-09 → 2013-02🇮🇹 Italy

Studying: Embryo's Genetic and Chromosomal Quality · NCT01636505

About this trial

The aim of this study is to performed a randomized controlled trial to evaluate the rate of genetic and chromosomal abnormalities in embryos obtained from GnRH-agonist long and GnRH-antagonist ovarian stimulation protocols. Patients will be prospectively randomized in two groups: the first undergoing controlled ovarian stimulation in GnRH-agonist long protocol and the second following GnRH-antagonist ovarian stimulation regimen. The end-points of the study include the number of genetically and chromosomally abnormal embryos, the pregnancy, the implantation and the healthy baby birth rate. T…

Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients

Unknown statusPhase 470 peopleRandomizedInstituto Valenciano de Infertilidad, IVI VALENCIA2011-05 → 2012-11🇪🇸 Spain

Studying: Infertility · NCT01353846

About this trial

The purpose of this study is to compare the natural cycle (without any medication) with the well-established artificial cycle in an egg donation program.

Maintenance Therapy of Levonorgestrel-releasing Intrauterine System (LNG-IUS) to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery

Unknown statusPhase 380 peopleRandomizedTaipei Veterans General Hospital, Taiwan2008-03 → 2009-03🇹🇼 Taiwan

Studying: Endometriosis · NCT01125488

About this trial

The recurrence rates of endometriosis reported in women 5 years after therapy with gonadotropin releasing hormone (GnRH) agonist were 74% for severe disease . No strategies to prevent the recurrence of endometriosis have been uniformly successful. Local progesterone treatment of endometriosis-associated dysmenorrhea with a levonorgestrel-releasing intrauterine system (LNG-IUS) for 12 months has resulted in a significant reduction in dysmenorrhea, pelvic pain and dyspareunia; a high degree of patient satisfaction; and a significant reduction in the volume of rectovaginal endometriotic nodules. …

Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children

Unknown statusPhase 4100 peopleUniversity of Pisa🇮🇹 Italy

Studying: Central Precocious Puberty · NCT00438217

About this trial

The goal of CPP-EDG 01 study is to assess possible genetic and/or environmental parameters which may influence the growth rate of children affected by precocious puberty. In this view, we are collecting clinical data and biological samples of children attended as outpatients at the Pediatric Endocrine Center of Pisa from 1998 to present (the study is still open). From biological (blood) samples, gene polymorphisms such as endocrine disruptor levels are determined and compared to different growth pattern of pediatric patients treated with different GnRH agonists.

Registered trials include ones that haven't published results yet. Trials are matched on the compound's name and code names (Gonadorelin, GnRH, Factrel) in the listed interventions.